A PHASE II RANDOMIZED NON COMPARATIVE STUDY ON THE ACTIVITY OF TRABECTEDIN OR GEMCITABINE + DOCETAXEL IN METASTATIC OR LOCALLY RELAPSED UTERINE LEIOMYOSARCOMA PRETREATED WITH CONVENTIONAL CHEMOTHERAPY

Trial Profile

A PHASE II RANDOMIZED NON COMPARATIVE STUDY ON THE ACTIVITY OF TRABECTEDIN OR GEMCITABINE + DOCETAXEL IN METASTATIC OR LOCALLY RELAPSED UTERINE LEIOMYOSARCOMA PRETREATED WITH CONVENTIONAL CHEMOTHERAPY

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs Trabectedin (Primary) ; Docetaxel; Gemcitabine
  • Indications Uterine leiomyoma
  • Focus Therapeutic Use
  • Acronyms TAUL
  • Most Recent Events

    • 21 Mar 2017 Planned primary completion date changed from 1 Sep 2016 to 1 Jul 2017.
    • 10 Nov 2016 According to a PharmaMar media release, data from this trial will be presented at the 21st Annual Meeting of the Connective Tissue Oncology Society (CTOS).
    • 22 Jun 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Sep 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top